Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 November 2022 | Story André Damons

The Department of Pharmacology at the University of the Free State (UFS), together with the Technology Innovation Agency (TIA), is hosting the first Indigenous Knowledge and Bio-Trade Indaba on the Bloemfontein Campus. The Department of Science and Innovation (DSI) and TIA are the sponsors of the event. 

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, will play host to the various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, innovation, and commercialisation of the IK-based research products. The Indigenous Knowledge System (IKS) for Health unit in the Department of Pharmacology within the UFS Faculty of Health Sciences was last year awarded an annual Technology Innovation Agency Platform (TIA) grant of R17 million for the next five years.

The research and teaching programme in the School of Clinical Medicine has since been rebranded and is now known as the African Medicines Innovation and Technology Development Platform (AMITD), which will strive to respond to community health needs and address industry research needs and challenges.

The indaba will showcase progress made by TIA and other entities in enriching the development and commercialisation of IK-based innovations. It will take place from 24 to 25 November 2022 in the Equitas Senate Hall at the UFS. 

Prof Matsabisa is the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19. He is also a visiting professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, and the Deputy President of the South African Society for Basic and Clinical Pharmacology.
 

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept